In conclusion, SMAC-mimetics targeting members of the IAP family, especially XIAP, offer a new strategy for the treatment of chemotherapy-resistant melanomas, particularly when used in combination with other drugs like Bortezomib, TRAIL or TRAIL-R agonists. Here, TNFSF10 is linked to melanoma.